JP7572007B2 - ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途 - Google Patents

ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途 Download PDF

Info

Publication number
JP7572007B2
JP7572007B2 JP2021527709A JP2021527709A JP7572007B2 JP 7572007 B2 JP7572007 B2 JP 7572007B2 JP 2021527709 A JP2021527709 A JP 2021527709A JP 2021527709 A JP2021527709 A JP 2021527709A JP 7572007 B2 JP7572007 B2 JP 7572007B2
Authority
JP
Japan
Prior art keywords
meibomian gland
composition
nmn
item
meibomian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021527709A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020262497A1 (https=
Inventor
雅夫 土居
毅 中嶋
麻実子 町田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Kyoto University NUC
Original Assignee
Senju Pharmaceutical Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd, Kyoto University NUC filed Critical Senju Pharmaceutical Co Ltd
Publication of JPWO2020262497A1 publication Critical patent/JPWO2020262497A1/ja
Application granted granted Critical
Publication of JP7572007B2 publication Critical patent/JP7572007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021527709A 2019-06-25 2020-06-24 ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途 Active JP7572007B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019117642 2019-06-25
JP2019117642 2019-06-25
PCT/JP2020/024916 WO2020262497A1 (ja) 2019-06-25 2020-06-24 ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途

Publications (2)

Publication Number Publication Date
JPWO2020262497A1 JPWO2020262497A1 (https=) 2020-12-30
JP7572007B2 true JP7572007B2 (ja) 2024-10-23

Family

ID=74060627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527709A Active JP7572007B2 (ja) 2019-06-25 2020-06-24 ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途

Country Status (7)

Country Link
US (1) US20220370484A1 (https=)
EP (1) EP3991795B1 (https=)
JP (1) JP7572007B2 (https=)
CN (1) CN114007693B (https=)
ES (1) ES2989969T3 (https=)
PL (1) PL3991795T3 (https=)
WO (1) WO2020262497A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119792334A (zh) * 2025-02-25 2025-04-11 中国农业大学 组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542296A (ja) 2005-05-25 2008-11-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置
JP2018535956A (ja) 2015-10-23 2018-12-06 ザ ジャクソン ラボラトリー 眼神経変性障害（例えば緑内障）の処置及び予防における使用のためのニコチンアミド
WO2020054795A1 (ja) 2018-09-14 2020-03-19 めぐみ 田中 老化防止剤及び老化防止方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968306T3 (pl) * 2013-03-15 2024-01-29 Washington University Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
JP2018100222A (ja) * 2015-04-20 2018-06-28 学校法人慶應義塾 角膜損傷の治療剤、改善剤または予防剤
US20170326161A1 (en) * 2015-12-10 2017-11-16 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof
US10898738B2 (en) * 2016-09-13 2021-01-26 Megumi Tanaka Visual function printing agent, and method for improving visual functions
JP6831407B2 (ja) 2019-02-22 2021-02-17 能美防災株式会社 火災受信機

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542296A (ja) 2005-05-25 2008-11-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置
JP2018535956A (ja) 2015-10-23 2018-12-06 ザ ジャクソン ラボラトリー 眼神経変性障害（例えば緑内障）の処置及び予防における使用のためのニコチンアミド
WO2020054795A1 (ja) 2018-09-14 2020-03-19 めぐみ 田中 老化防止剤及び老化防止方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILLS, K.F. et al.，Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decli，Cell Metabolism，2016年，Vol.24，pp.795-806

Also Published As

Publication number Publication date
EP3991795A1 (en) 2022-05-04
EP3991795A4 (en) 2023-07-19
CN114007693B (zh) 2024-07-12
EP3991795B1 (en) 2024-09-11
PL3991795T3 (pl) 2025-01-13
CN114007693A (zh) 2022-02-01
US20220370484A1 (en) 2022-11-24
JPWO2020262497A1 (https=) 2020-12-30
WO2020262497A1 (ja) 2020-12-30
ES2989969T3 (es) 2024-11-28

Similar Documents

Publication Publication Date Title
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
CN103037692B (zh) 用于抑制肌萎缩的方法
EP3920912B1 (en) Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
TW202033193A (zh) 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
US9572825B2 (en) Compositions and methods for treating huntington's disease
WO2023220404A1 (en) Treatment of non-alcoholic steatohepatitis
TW202327589A (zh) 肝病之組合療法
US20180305396A1 (en) Deuterated compounds
JP7572007B2 (ja) ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途
CN104173286B (zh) 氮卓斯汀组合物和用途
US20200246314A1 (en) Dyslipidemia therapeutic agent
CN114667142A (zh) 治疗肝脏病症
RU2822512C2 (ru) Новое применение никотинамид мононуклетида (nmn) и никотинамид рибозида (nr)
EP3213751A1 (en) Phacosclerosis inhibitor
WO2002000225A1 (en) 7-hydroxyepiandrosterone having neuroprotective activity
KR20220134529A (ko) 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론
CN108218945B (zh) 去氧胆酸衍生物、其制备方法、药物组合物及用途
US20240415862A1 (en) Methods for treatment of menopausal syndromes
JPWO2018199224A1 (ja) 抗アレルギー剤
EP4166137A1 (en) Therapeutic agent for fatty liver disease
CA3171746A1 (en) Benzimidazole compound for the treatment of metabolic disorders
EA051671B1 (ru) Ганаксолон для использования в лечении комплекса туберозного склероза
JP2013170165A (ja) 筋萎縮性側索硬化症予防治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230523

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230721

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241002

R150 Certificate of patent or registration of utility model

Ref document number: 7572007

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150